Charting API Market Growth and Opportunity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charting API Market Growth and Opportunity
The year 2007 was slow for approvals for new molecular entities and overall pharmaceutical industry growth. Big Pharma seeks relief in a growing biologics portfolio.


Pharmaceutical Technology



Table II: Top products by 2007 US sales.
US sales. US sales of prescription pharmaceuticals tallied $286.5 billion in 2007, according to IMS Health (see Table II). Eight of the top 10 global products (Lipitor, Nexium, Seretide/Advair, Plavix, Seroquel, Singulair, Enbrel, and Aranesep) were also ranked in the top 10 in US sales. Lipitor took top billing with US sales of $8.1 billion in 2007. Two drugs—Wyeth's "Prevacid" (lansoprazole) and Amgen's "Epogen" (epoetin alfa) made the top 10 US list but not the top 10 global rankings.

The rise of biotech drugs

Global sales of prescription biotechnology drugs increased 12.5% to more than $75 billion in 2007, according to IMS Health. This rate of growth was nearly double the rate of growth of 6.4% for the overall global pharmaceutical market, but down from the 18.2% growth for biotech products experienced in 2006. The biotech drug market, however, represents only about 10% of the global pharmaceutical market, which was valued at $712 billion in 2007. The US remains the largest market for biotech products and holds 56% of the global market.

Twenty-two biotech products generated sales exceeding $1 billion in 2007, compared with just six products in 2002, according to IMS. Enbrel was the top biotech product in 2007, followed by Aranesp. J&J's and Schering-Plough's (Kenilworth, NJ) "Remicade" (infliximab ) was third with global sales of $4.2 billion, and Roche's (Basel, Switzerland) "Mabthera"/"Rituxan" (rituximab) was fourth with sales of $3.7 billion. Amgen's "Neulasta" (pegfilgrastim) ranked fifth with global sales of $3.5 billion.

IMS estimates biotech products represent 25% of the total pharmaceutical pipeline. The firm projects that six products with market potential of $1 billion are expected to be launched by 2009.

Innovation drought


Table III: New molecular entities approvals, January 2007–May 2008.*
The level of product innovation, as measured by the number of approvals of new molecule entities (NMEs) and new biologics license applications (BLAs) by CDER, reached a recent low in 2007. In 2007, CDER approved 19 new drugs (17 NMEs and 2 BLAs) (see Table III). These levels represent a slight decline from approvals in 2006 and 2007 and a steep decrease from 2004. CDER approved 22 new drugs in 2006 (18 NMEs and 4 BLAs), 20 new drugs in 2005 (18 NMEs and 2 BLAs), and 36 new drugs (31 NMEs and 5 BLAs) in 2004, according to FDA data.

Generics' threat

As innovator companies struggle, opportunities for generic-drug companies are fairly strong. Over 150 products, including 20 blockbusters, with $77 billion in total branded drug sales in the US, are coming off patent through 2012, according to data from the scientific business of Thomson Reuters. Some major new generic launches in 2007 included: ceterizine hydrogen chloride (HCl), carvediol, pantoprazole sodium, zolpidem tartrate, risedronate sodium, and valacyclovir HCl. In 2008, 25 products will lose patent protection in the US. Some anticipated generic launches of 2008 include memantine HCl, topiramate, risperidone, levetiracetam, ropinirole HCl, alfuzolin HCl, eplerenone, and rocuronium bromide. For 2009, there are 29 molecules with new chemical entity exclusivity expiring and therefore exposed to Paragraph IV patent challenge in 2008. Some possible patent challenges in 2008 are for duloxetine HCL, pregabalin, and tiotropium bromide (1).

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,

Reference

1. P. Van Arnum, "Rocky Outlook for Pharmaceuticals," Pharm. Technol. Sourcing and Management 4 (4), 2008.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here